Nicotinic receptors as targets for therapeutic discovery

Expert Opinion on Drug Discovery

Volumn 2, Issue 9, 2007, Pages 1185-1203

  Lippiello, P M ^a   Bencherif, M ^a   Hauser, T A ^a   Jordan, K G ^a   Letchworth, S R ^a   Mazurov, A A ^a  

^a TARGACEPT INC   (United States)

Author keywords

Acetylcholine; Analgesia; Cognition; Depression; Inflammation; Neurodegeneration; Nicotinic receptors; Schizophrenia

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; ABT 894; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; AZD 3480; BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR STIMULATING AGENT; CAP 55; CHOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; ISPRONICLINE; LEVODOPA; MECAMYLAMINE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NICOTINE; NICOTINE PATCH; NICOTINIC AGENT; NICOTINIC RECEPTOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE; SSR 180711A; TC 1698; TC 2696; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ALZHEIMER DISEASE; ANALGESIA; ANALGESIC ACTIVITY; ANTINOCICEPTION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BRAIN ISCHEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INFLAMMATORY DISEASE; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 34848883088     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.9.1185     Document Type: Review

References (188)

1. ISHII M, KURACHI Y: Muscarinic acetylcholine receptors. Curr. Pharm. Des. (2006) 12:3573-3581.
2. DANI JA, BERTRAND D: Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. (2007) 47:699-729.
3. GOTTI C, ZOLI M, CLEMENTI F: Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci. (2006) 27:482-491.
4. LUKAS RJ, CHANGEUX JP, LE NOVERE N et al.: International union of pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev. (1999) 51:397-401.
5. BENCHERIF M, SCHMITT JD: Targeting neuronal nicotinic receptors: a path to new therapies. Curr. Drug Targets CNS Neurol. Disord. (2002) 1:349-357.
6. ASTLES PC, BAKER SR, BOOT JR, BROAD LM, DELL CP, KEENAN M: Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr. Drug Targets CNS Neurol. Disord. (2002) 1:337-348.
7. BREINING SR: Recent developments in the synthesis of nicotinic acetylcholine receptor ligands. Curr. Top. Med. Chem. (2004) 4:609-629.
8. GATTO GJ, BOHME GA, CALDWELL WS et al.: TC- 1734: an orally active ncuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotcctive and long-lasting cognitive effects. CNS Drug Rev. (2004) 10:147-166.
9. MARTIN LF, FREEDMAN R: Schizophrenia and the α7 nicotinic acetylcholine receptor. Int. Rev. Neurobiol. (2007) 78:225-246.
10. PAVLOV VA, TRACEY KJ: Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem. Soc. Trans. (2006) 34:1037-1040.
11. QUIK M, MCINTOSH JM: Striatal α6* nicotinic acetylcholine receptors: potential targets for Parkinssons disease therapy. J. Pharmacol. Exp. Ther. (2006) 316:481-489.
12. SCOTT DA, MARTIN M: Exploitation of the nicotinic anti-inflammatory pathway for the treatment of epithelial inflammatory diseases. World J Gastroenterol. (2006) 12:7451-7459.
13. MERRETT MN, MORTENSEN N, KEITLEWELL M, JEWELL DO: Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut (1996) 38:362-364.
14. SOPORI ML, KOZAK W, SAVAGE SM, GENG Y, KLUGER MJ: Nicotine-induced modulation of T cell function. Implications for inflammation and infection. Adv. Exp. Med. Biol. (1998) 437:279-289.
15. WEHRWEIN E, THOMPSON SA, COULIBALY SF, LINN DM, LINN CL: Acetylcholine protection of adult pig retinal ganglion cells from glutamate-induced excitotoxicity. Invest. Ophthalmol. Vis. Sci. (2004) 45:1531-1543.
16. LEE SJ, NAKAMURA Y, DE GROAT WC: Effect of (+/-)-epibatidine, a nicotinic agonist, on the central pathways controlling voiding function in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2003) 285:R84-R90.
17. MISERY L: Nicotine effects on skin: are they positive or negative? Exp. Dermatol. (2004) 13:665-670.
18. NGUYEN VT, ARREDONDO J, CHERNYAVSKY AI, PITTELKOW MR, KITAJIMA Y, GRANDO SA: Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch. Dermatol. (2004) 140:327-334.
19. HARRIST A, BEECH RD, KING SL et al.: Alteration of liippocampal cell proliferation in mice lacking the β2 subunit of the neuronal nicotinic acetylcholine receptor. Synapse (2004) 54:200-206.
20. LEVIN ED, MCCLERNON FJ, REZVANI AH: Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopbarmacology (Berl.) (2006) 184(3-4):523-539.
21. LEVIN ED, CHRISTOPHER NC: Persistence of nicotinic agonist RJR 2403-induced working memory improvement in rats. Drug Dev. Res. (2002) 55:97-103.
22. MARTI BARROS DM, RAMIREZ MR, DOS REIS EA, IZQUIERDO I: Participation of hippocampal nicotinic receptors in acquisition, consolidation and retrieval of memory for one trial inhibitory avoidance in rats. Neuroscience (2004) 126:651-656.
23. BUCCAFUSCO JJ, BENCHERIF M, LETCHWORTH SR, LIPPIELLO PM: Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharm. Sci. (2005) 26:352-360.
24. HAHN B, SHARPLES CG, WONNACOTT S, SHOAIB M, STOLERMAM IP: Attentional effects of nicotinic agonists in rats. Neuropharmacology (2003) 44:1054-1067.
25. LEVIN ED, CONNERS CK, SILVA D, CANU W, MARCH J: Effects of chronic nicotine and methylphenidate in adults with attention deficit/ hyperactivity disorder. Exp. Clin. Psychopharmacol. (2001) 9:83-90.
26. RADCLIFF KA, DANI JA: Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J. Neurosci. (1998) 18:7075-7083.
27. MANN EO, GREENFIELD SA: Novel modulatory mechanisms revealed by the sustained application of nicotine in the guinea-pig hippocampus in vitro. J. Physiol. (2003) 551:539-550.
28. MATSUYAMA S, MATSUMOTO A: Epibatidine induces long-term potentiation (LTP) via activation of α4β2 nicotinic acetylcholine receptors (nAChRs) in vivo in the intact mouse dentate gyrus: both α7 and α4β2 nAChRs essential to nicotinic LTP. J. Pharm. Sci. (2003) 93:180-187.
29. FUJII S, JI Z, MORITA N, SUMIKAWA K: Acute and chronic nicotine exposure differentially facilitate the induction of LTP. Brain Res. (1999) 846:137-143.
30. KENNY PJ, FILE SE, RATTRAY M: Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Res. Mol. Brain Res. (2000) 85:234-238.
31. BELLUARDO N, MUDO G, BLUM M, AMATO G, FUXE K. Neurotrophic effects of central nicotinic receptor activation. J. Neurol. Trans. Supp. (2000) 60:227-245.
32. JONNALA RR, TERRY AV Jr, BUCCAFUSCO JJ: Nicotine increases the expression of high affinity nerve growth factor receptors in both in vitro and in vivo. Life Sci. (2002) 70:1543-1554.
33. HERNANDEZ CM, TERRY AV JR: Repeated nicotine exposure in rats: effects on memory function, cholinergic markers and nerve growth Factor. Neuroscience (2005) 130:997-1012.
34. HEISENBERG CP, COOPER JD, BERKE J, SOFRONIEW MV: NMDA potentiates NGF-induced sprouting of septal cholinergic fibres. Neuroreport (1994) 5:413-416.
35. LAPCHAK PA, ARAUJO DM, HEFTI F: Effects of chronic nerve growth factor treatment on hippocampal [3H]cytisine/nicotinic binding sites and presynaptic nicotinic receptor function following fimbrial transections. Neuroscience (1994) 60:293-298.
36. WANG H, SUN X- Desensitized nicotinic receptors in brain. Brain Res. Brain Res. Rev. (2005) 48:420-437.
37. FUJII S, JI Z, SUMIKAWA K: Inactivation of α7 ACh receptors and activation of non-α7 ACh receptors both contribute to long term potentiation induction in the hippocampal CA1 region. Neurosci. Lett. (2000) 286:134-138.
38. JI D, LAPE R, DANI JA. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron (2001) 31:131-141.
39. WHITEHOUSE PJ: The cholinergic deficit in Alzheimer s disease. J. Clin. Psychiat. (1998) 59:19-22.
40. NEWHOUSE PA, POTTER A, SINGH A. Effects of nicotinic stimulation on cognitive performance. Curr. Opin. Pharmacol. (2004) 4:36-46.
41. SACCO KA, BANNON KL, GEORGE TP: Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J. Psychopharm. (2004) 18:457-474.
42. WEVERS A, MONTEGGIA L, NOWACKI S et al.: Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylaed-tau protein. Eur. J. Aeurosci. (1999) 11:2551-2565.
43. NAGELE RG, D'ANDREA MR, WANG H-Y: intraneuronal accumulation of β-amyloid 1-42 is mediated by the α7 nicotinic acetylcholine receptor in Alzheimer s disease. Neuroscience (2002) 110:199-211.
44. D ANDREA MR, NAGELE RG: Targeting the α7 ncitonic acetylcholine receptor to reduce amyloid accumulation in Alzheimer s disease pyramidal neurons. Curr. Pharmaceut. Des. (2006) 12:677-684.
45. WU J, KUO Y-P, GEORGE AA, XU L, HU J, LUKAS RJ: β-Amyloid directly inhibits human α4β2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J. Biol. Chem. (2004) 279:37842-37851.
46. NORDBERG A, HELLSTROM-LINDAHL E, LEE M et al.: Chronic nicotine treatment reduces β-amyloidosis in the brain of a mouse model of Alzheimer s disease (APPsw). J. Neurochem. (2002) 81:655-658.
47. LLEO A, GREENBERG SM, GROWDON JH: Current pharmacotherapy for Alzheimer's disease. Annu. Rev. Med. (2006) 57:513-533.
48. SAMANTA MK, WILSON B, SANTHI K, KUMAR KP, SURESH B: Alzheimer disease and its management: a review. Am. J. Ther. (2006) 13:516-526.
49. DUNBAR GC, INGLIS F, KUCHIBHATLA R, SHARMA T, TOMLINSON M, WAMSLEY J: Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J. Psychopharmacol. (2007) 21:171-178.
50. HELLSTROM-LINDAHL E, COURT J, KEVERNE J et al.: Nicotine reduces A β in the brain and cerebral vessels of APPsw mice. Eur. J. Neurosci. (2004) 19:2703-2710.
51. PARAIN K, HAPDEY C, ROUSSELET E, MARCHAND V, DUMERY B, HIRSCH EC: Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res. (2003) 984:224-232.
52. TAKADA Y, YONEZAWA A, KUME T et al.: Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. (2003) 306:772-777.
53. O NEILL MJ, MURRAY TK, LAKICS V, VISANJI NP, DUTY S: The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr. Drug Targets CNS Neurol. Disord. (2002) 1:399-411.
54. FLORES CM, HARGREAVES KM: Neuronal nicotinic receptors: new targets in the treatment of pain. In: Neuronal Nicotinic Receptors: Phamacology and Therapeutic Opportunities. Arneric SR Brioni JD (Eds), Wiley-Liss, New York, USA (1998):3 59-378.
55. CORDERO-ERAUSQUIN M, CHANGEUX JP: Tonic nicotinic modulation of serotonergic transmission in the spinal cord. Proc. Natl. Acad. Sci. USA (2001) 98:2803-2807.
56. RUETER LE, MEYER MD, DECKER MW: Spinal mechanisms underlying A-85380-induced cflects on acute thermal pain. Brain Res. (2000) 872:93-101.
57. FLORES CM: The promise and pitfalls of a nicotinic cholinergic approach to pain management. Pain (2000) 88:1-6.
58. CAGGIULA AR, EPSTEIN LH, PERKINS KA, SAYLOR S: Different methods of assessing nicotinc-induced antinociception may engage different neural mechanisms. Psychopharmacology (1995) 122:301-306.
59. BANNON AW, DECKER MW, HOLLADAY MW et al.: Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science (1998) 279:77-81.
60. SATKUNANATHAN N, LIVETT B, GAYLER K, SANDALL K, DOWN J, KHALIL Z: α-conotoxin Vc 1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurons. Brain Res. (2005) 1059:149-158.
61. GENZEN J, D MCGEHEE: Nicotinic modulation of GABAergic synaptic transmission in the spinal cord dorsal horn. Brain Res. (2005) 1031:229-237.
62. DECKER MW, RUETER LE, BITNER RS: Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Curr. Top. Med. Chem. (2004) 4:369-384.
63. BITNER RS, NIKKEL Al, CURZON P et al.: Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res. (2000) 871:66-74.
64. LESTER HA, FONCK C, TAPPER AR et al.: Hypersensitive knock-in mouse strains identify receptors and pathways for nicotine action. Curr. Opin. Drug Dis. Dev. (2003) 6:633-639.
65. RUETER LE, DECKER MW, BITNER RS: Improving the therapeutic window in the treatment of pain with nicotinic ligands. Drug Disc. Today Ther. Strat. (2004) 1:89-96.
66. VINCLER MA, EISENACH JC: Plasticity of spinal nicotinic acetylcholine receptors following spinal nerve ligation. Neurosci. Res. (2004) 48:139-145.
67. VINCLER MA, EISENACH JC: Knock down of the α nicotinic acetylcholine receptor in spinal nerve-ligated rats alleviates mechanical allodynia. Pharmacol. Biochem. Behav. (2005) 80:135-143.
68. RAMIREZ-LATORRE J, YU CR, QU X, PERIN F, KARLIN A, ROLE L: Functional contributions of α5 subunit to neuronal acetylcholine receptor channels. Nature (1996) 380:347-351.
69. DAMAJ MI, MEYER EM, MARTIN BR: The antinociceptive effects of α7 nicotinic agonists in an acute pain model. Neurophamacology (2000) 39:2785-2791.
70. WANG Y, SU DM, WANG RH, LIU Y, WANG H: Antinociceptive effects of choline against acute and inflammatory pain. Neuroscience (2005) 132:49-56.
71. MORIOKA N, ABJIN J, MORITA K et al.: Antinociceptive effect of nicotine on tibial nerve transection-induced neuropathic pain. Soc. Neurosci. Abstr. (2006) 803:13.
72. DAMAJ MI, MARUBIO L, MARTIN BR: Involvement of α7 nicotinic receptors in acute and chronic pain transmission. Soc. Neurosci. Abstr. (2003) 693:12.
73. DE JONGE WJ, VAN DER ZANDEN EP, THE FO et al.: Stimulation of the vagus nerve attenuates macrophage activation by activating the JAK2-STAT3 signaling pathway. Nat. Immunol. (2005) 6:844-851.
74. VAN WESTERLOO DJ, GIEBELEN IA, FLORQUIN S et al: The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology (2006) 130:1822-1830.
75. VINCLER M, WITTENAUER S, PARKER R, ELLISON M, OLIVERA BM, MCINTOSH JM: Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors. Proc. Natl. Acad. Sci. USA (2006) 103:17780-17784.
76. CLARK RJ, FISCHER H, NEVIN ST, ADAMS DJ, CRAIK DJ:The synthesis, tructural characterization, and receptor pecificity of the α-conotoxin Vc1.1. J. Biol. Chem. (2006) 281:23254-23263.
77. ELLISON M, HABERLANDT C, GOMEZ-CASATI ME et al.: α-RgIA: a novel conotoxin that specifically and potently blocks the α9α10 nAChR. Biochemitry (2006) 45:1511-1517.
78. LIPS KS, PFEIL U, KUMMER W: Coexpression of α9 and α10 nicotinic acetylcholine receptors in rat dorsal root ganglion neurons. Neuroscience (2002) 15:1-5.
79. PENG H, FERRIS RL, MATMEWS T, HIEL H, LOPEZ-ALBAITERO A, LUSTIG LR: Characterization of the human nicotinic acetylcholine receptor subunit α (alpha) 9 (CHRNA9) and α (alpha) 10 (CHRNA10) in lymphocytes. Life Sci. (2004) 76:263-280.
80. JAIN KK. Modulators of nicotinic acetylcholine receptors as analgesics. Curr. Opin. Investig. Drugs (2004) 5:76-81.
81. JANOWSKY DS, EL-YOUSEF MK, DAVIS JM, SEKERKE HJ: A chorinersic-adrenereic hypothesis of mania and depression. Lancet (1972) 2:632-635.
82. AUBIN HJ, TILIKETE S, BARRUCAND D: Depression and Smoking. Encephale (1996) 22:17-22.
83. SEMBA J, MATAKI C, YAMADA S, NANKAI M, TORU M: Anddepressant-like effects of chronic nicotine on learned helplessness paradigm in rats. Biol. Psychiatry (1998) 43:389-391.
84. VAZQUEZ-PALACIOS G, BONILLA-JAIME H, VELAZQUEZ-MOCTEZUMA J: Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine. Pharmacol. Biochem. Behav. (2004) 78:165-169.
85. TIZABI Y, OVERSTREET DH, REZVANI AH et al.: Antidepressant effects of nicotine in an animal model of depression. Pychopharmacology (Berl.) (1999) 142:193-199.
86. SALIN-PASCUAL RJ, ROSAS M, JIMENEZ-GENCHI A, R]VERA-MEZA BL, DELGADO-PARRA V: Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J. Clin. Pychiatry (1996) 57:387-389.
87. SLEMMERJE, MARTIN BR, DAMAJ MI: Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. (2000) 295:321-327.
88. FRYER JD, LUKAS RJ: Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. (1999) 288:88-92.
89. RABENSTEIN RL, CALDARONE BJ, PICCIOTTO MR: The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not β2- or α7-nicotinic acetylcholine receptor subunit knockout mice. Pychopharmacology (Berl.) (2006) 189:395-401.
90. SHYTLE RD, SILVER AA, LUKAS RJ, NEWMAN MB, SHEEHAN DV, SANBERG PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol. Psychiatry (2002) 7:525-535.
91. SACCO KA, VESSICCHIO JC, GEORGE TP: Nicotinic antagonist augmentation of SSRI antidepressants: preliminary results. 59th Annual Convention and Scientific Program of the Society of Biological Pychiatry, New York, NY. (29 April - 1 May 2004). (Abstract).
92. CALDARONE BJ, HARRIST A, CLEARY MA, BEECH RD, KING SL, PICCIOTTO MR: High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol. Psychiatry (2004) 56:657-664.
93. LABARCA C, SCHWARZ J, DESHPANDE P et al.: Point mutant mice with hypersensitive α4 nicotinic receptors show doparninergic deficits and increased anxiety. Proc. Natl. Acad. Sci. USA (2001) 98:2786-2791.
94. MINEUR YS, SOMENZI O, PICCIOTTO MR: Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology (2007) [Epub ahead of print].
95. WONG AHC, VAN TOL HHM: Schizophrenia: from phenomenology to neurobiology. Neurosci. Biobehav. Rev. (2003) 27:269-306.
96. LEONARD S, ADLER LE, BENHAMMOU K et al.: Smoking and mental illness. Pharmacol. Biochem. Behav. (2001) 70:561-570.
97. FREEDMAN F, HALL M, ADLER LE, LEONARD S: Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry (1995) 38:22-33.
98. GUAN ZZ, ZHANGX, BLENNW K et al.: Decreased protein level of nicotinic acetylcholine receptor α7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 10:1779-1782.
99. BREESE CR, ADAMS C, LOGEL J et al.: Comparison of the regional expression of nicotinic acetylcholine receptor α7 mRNA and [I 25I]-α-bungarotoxin binding in human postmortem brain. J. Comp. Neurol. (1997) 387:385-398.
100. MANSVELDER HD, MCGEHEE DS: Long-term potentiation of excitatory inputs to brain reward area by nicotine. Neuron (2000) 27:349-357.
101. EGEA J, ROSA AO, SOBRADO M, GANDIA L, LOPEZ MG, GARCIA AG: Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in α nicotinic receptor knockout mice. Neuroscience (2007) 145:866-872.
102. LEONARD S, FREEDMAN R: Genetics of chromosome 15q13-q14 in schizophrenia. Biol. Psychiatry (2006) 60:115-122.
103. WALKER E, KESTLER L, BOLLINI A, HOCHMAN KM: Schizophrenia: etiology and course. Annu. Rev. Psychol. (2004) 55:401-430.
104. FENTON WS, STOVER EL, INSEL TR: Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective. Psychopharmacology (2003) 169:365-366.
105. MEYER EM, DE FIEBRE DM, HUNTER BE, SIMPKINS CE, FRAUWORTH N, DE FIEBRE NE: Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev. Res. (1994) 31:127-134.
106. ARENDASH GW, SENGSTOCK GJ, SANBERG PR, KEM WR: Improved learning and memory in aged rats with chronic administration of nicotinic receptor agonist GTS-21. Brain Res. (1995) 674:252-259.
107. WOODRUFF-PAK DS, LI YT; KAZMI A, KEM WR: Nicotinic cholinergic system involvement in eyeblink classical conditioning in rabbits. Behav. Neurosci. (1994) 108:486-493.
108. BRIGGS CA, ANDERSON DJ, BRIONI JD et al.: Functional characterization of a novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. (1997) 57:231-241.
109. SIMOSKY JK, STEVENS KE, KEM WR, FREEDMAN R: Intragastric DMXB-A, an α7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol. Psychiatry (2001) 50:493-500.
110. HURST RS, HAJOS M, RAGGENBASS M et. al.: A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J. Neurosci. (2005) 25:4396-4405.
111. HAJ S M, HURST RS, HOFFMANN WE et al.: The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain shoes and restores auditory gating deficits in anesthetized rats. JPET (2005) 312:1213-1222.
112. BETTANY JH, LEVIN ED: Ventral hippocampal α7 nicotinic receptor blockade and chronic nicotine effects on memory performance in the radial-arm maze. Pharmacol. Biochem. Behav. (2001) 70:467-474.
113. ADDY NA, NAKIJAMA A, LEVIN ED: Nicotinic mechanisms of memory: effects of acute local DhPE and MLA infusions in the basolateral amygdala. Brain Res. Cogn. Brain Res. (2003) 16:51-57.
114. ADLER LE, OLINCY A, WALDO MC et al.: Schizophrenia, sensory gating and nicotinic receptors. Schizophr. Bull. (1998) 24:189-202.
115. ROSS RG, OLINCY A, HARRIS JG et al.: Anticipatory saccades during smooth pursuit eye movements and familial transmission of schizophrenia. Biol. Psychiatry (1998) 44:690-697.
116. CILIA J, CLUDERAY JE, ROBBINS MJ et al.: Reversal of isolarion-rearing-induced PPI deficits by an α7 nicotinic receptor agonist. Pychopharmacology (2005) 182:214-219.
117. VAN KAMPEN M, SELBACH K, SCHNEIDER R, SCHIEGEL E, BOESS F, SCHREIBER R: AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors. Pychopharmacology (2004) 172:375-383.
118. LEVIN ED, BETTEGOWDA C, BLOSSER J, GORDON J: AR-R 17779, an 2a7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol. (1999) 10:675-680.
119. PICHAT P, BERGIS OE, TERRANOVAJP et al.: SSR180711A, a novel selective α7 nicotinic receptor partial agonist. III. Effects in models predictive of therapeutic activity on cognitive symptoms of schizophrenia. Soc. Neurosci. Abstr. (2004) 34:583.3.
120. BERGIS OE, PICHAT P, SANTAMARIA R et al.: SSR180711A, a novel selective α7 nicotinic receptor partial agonist. II. Effects in models predictive of therapeutic activity on cognitive symptoms of Alzheimer's disease. Soc. Neurosci. Abstr. (2004) 34:583.2.
121. OLINCY A, HARRIS JG, JOHNSON LL et al: Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry (2006) 63:630-638.
122. QUIK M: Smoking, nicotine and Parkinson s disease. Trends Neurosci. (2004) 27:561-568.
123. ALLAM MF, CAMPBELL MJ, HOFMAN A, DEL CASTILLO AS, FERNANDEZ-CREHUET NAVAJAS R: Smoking and Parkinsods disease: systematic review of prospective studies. Mov. Disord. (2004) 19:614-621.
124. BALFOUR DJ, FAGERSTROM KO: Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol. Ther. (1996) 72:51-81.
125. WONNACOTT S: Presynaptic nicotinic ACh receptors. Trends Neurosci. (1997) 20:92-98. 127.
126. SALMINEN O, MURPHY KL, MCINTOSH JM et al.: Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmzacol. (2004) 65:1526-1535.
127. LE NOVERE N, ZOLI M, LENA C et al.: Involvement of a6 nicotinic receptor subunit in nicotine-eficited locomotion, demonstrated by in vivo antisense oligonucleotide infusion. Neurareport (1999) 10:2497-2501.
128. LUETJE CW. Getting past the asterisk: the subunit composition of presynaptic nicotinic receptors that modulate striatal dopamine release. Mol. Pharmacol. (2004) 65:1333-1335.
129. GRINEVICH VP, LETCHWORTH SR, LINDENBERGER KA et al.: Heterologous expression of human {a}6{β}4{β}3{α}5 nicotinic acetylcholine receptors: binding properties consistent with their natural expression require quaternary subunit assembly including the {α}5 subunit. J. Pharmacol. Exp. Ther. (2005) 312:619-626.
130. KAISER S, WONNACOTT S: α-Bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. (2000) 58:312-318.
131. GOTTI C, MORETTI M, BOHR I et al.: Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol. Dis. (2006) 23:81-489.
132. KULAK JM, MCINTOSH JM, QUIK M: Loss of nicotinic receptors in monkey striatum. after 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine treatment is due to a decline in α-conotoxin MII sites. Mol. Pharmacol. (2002) 61:230-238.
133. ABIN-CARRIQUIRY JA, MCGREGOR-ARMAS R, COSTA G, URBANAVICIUS J, DAJAS F: Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra. Neurvtox. Res. (2002) 4:133-139.
134. DOMINO EF, NI L, ZHANG H: Nicotine alone and in combination with L-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys. Exp. Neurol. (1999) 158:414-421.
135. SCHNEIDER JS, POPE-COLEMAN A, VAN VELSON M, MENZAGHI F, LLOYD GK: Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov. Disord. (1998) 13:637-642.
136. PICCIOTTO MR, ZOLI M: Nicotinic receptors in aging and dementia. J. Neurobiol. (2002) 53:641-655.
137. JEYARASASINGAM G, TOMPKINS L, QUIK M: Stimulation of non-α7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience (2002) 109:275-285.
138. JANSON AM, FUXE Y, AGNATI LF et al.: Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriaral doparnine system of the male rat after partial hernitransection. Brain Res. (1988) 455:332-345.
139. FUXE K, JANSON AM, JANSSON A, ANDERSSON K, ENEROTH P, AGNATI LF: Chronic nicotine treatment increases dopamine levels and reduces doparnine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection. Naunyn Schmiedebergs Arch. Pharmacol. (1990) 341:171-181.
140. RYAN RE, ROSS SA, DRAGO J, LOIACONO RE: Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprorection in α4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol. (2001) 132:1650-1656.
141. COSTA G,ABIN-CARRIQUIRY JA, DAJAS F: Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the subscantia nigra. Brain Res. (2001) 888:336-342.
142. QUIX M, PARAMESWARAN N, MCCALLUM SE et al.: Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J. Neurochem. (2006) 98:1866-1875.
143. QUIK M, CHEN L, PARAMESWARAN N, XIE X, LANGSTON JW, MCCALLUM SE: Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-lesioned primates. J. Neurosci. (2006) 26:4681-4689.
144. KELTON MC, KAHN HJ, CONRATH CL, NEWHOUSE PA: The effects of nicotine on Parkinson's disease. Brain Cogn. (2000) 43:274-282.
145. COSFORD ND, BLEICHER L, HERBAUT A et al.: (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel and-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. (1996) 39:3235-3237.
146. THE PARKINSON STUDY GROUP: Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology (2006) 66:408-410.
147. MCGILLIGANVE, WALLACE JMW, HEAVEY PM, RIDLEY DL, ROWLAND IR. Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis. Inflamm. Bowel Dis. (2007) 13:108-115.
148. MIAO FJP, GREEN P, BENOWITZ N, LEVINE JD: Vagal modulation of spinal nicotine-induced inhibition of the inflammatory response mediated by descending andnociceptive controls. Neuropharmacology (2003) 45:605-611.
149. BOROVIKOVA LV, IVANOVA S, NARDI D et al.: Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Autonomic Neurosci. Basic Clin. (2000) 85:141-147.
150. BOROVIKOVA EV, IVANOVA S, ZHANG M et al.: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature (2000) 405:458-462.
151. WANG H, YU M, OCHANI M et al.: Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature (2003) 421:384-387.
152. HUSTON JM, OCHANI M, ROSAS-BALLINA M et al.: Splenectomy inactivates the cholinergic and-inflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J. Exp. Med. (2006) 203:1623-1628.
153. WANG H, LIAO H, OCHANI M et al.: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. (2004) 10:1216-1221.
154. VAN WESTERLOO DJ, GIEBELEN IAJ, FLORQUIN S et al.: The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J. Infect. Dis. (2005) 191:2138-2148.
155. SHAW S,BENCHERIF M, MARRERO MB: Janus kinase 2, an early target of α7 nicotinic acetylcholine recTetor-mediated neuroprotection against Aβ-(1-42) amyloid. J. Biol. Chem. (2002) 277:44920-44924.
156. MARRERO MB, PAPKE RI, BHATTI BS, SHAW S, BENCHERIF M: The neuroprotective eflect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC- 1698), a novel α7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. J. Pharmacol. Exp. Ther. (2003) 309:16-27.
157. YOSHIKAWA H, KUROKAWA M, OZAKI N et al.: Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of 1-κB phosphorylation and NF-κB transcriptional activity through nicotinic acetylcholine receptor κ7. Clin. Exp. Immunol. (2006) 146:116-123.
158. SAEED RW, VARMA S, PENG-NEMEROFF T et al.: Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J. Exp. Med. (2005) 201:1113-1123.
159. PAVLOV VA, OCHANI M, YANG LH et al.: Selective ↓-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit. Care Med. (2007) 35:1-6.
160. RUSSO C, POLOSA R: TNF-α as a promising therapeutic target in chronic asthma: a lesson hom rheumatoid arthritis. Clin. Sci. (2005) 109:135-142.
161. GüNDISH D: Nicotinic acetylcholine receptors and imaging. Curr. Pharm. Design. (2000) 6:1143-1157.
162. VOLKOW ND, DING Y-S, FOWLER JS et al.: Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol. Psychiatry (2001) 49:211-220.
163. SIHVER W, NORDBERG A, LÅNGSTRÖM B et al.: Development of ligands in vivo imaging of cerebral nicotinic receptors. Behav. Brain Res. (2000) 113:143-157.
164. GRÜNWALD F, BIERSACK H-J, KUSCHINSKY W: Nicotine receptor mapping. Eur. J. Nucl. Med. (1996) 23:1012-1013.
165. 11C-labeled (S)-aicotine, (S)-3-methyl-5-(1-methyl-2-pyrrohdinyl)isoxazole, and (RS)-1-methyl-2-(3-pyridyl)azeddine as nicotinic receptor ligands for positron emission tomography studies. J. Neurochem. (1998) 71:1750-1760.
166. VALETTE H, BOTTLAENDER M, DOLLE F, DOLCI L, SYROTA A, CROUZEL C: An attempt to visualize baboon brain nicotinic receptors with N-[11C]ABT-418 and N-[11C]methyl-cyrisine. Nucl. Med. Commun. (1997) 18:164-168.
167. KOZIKOWSKI All CHELLAPPAN SK, HENDERSON D et al.: Acetylenic pyridines for use in PET imaging of nicotinic receptors. ChemMedChem (2007) 2:54-57.
168. FUJITA M, ICHISE M, ZOGHBI S et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann. Neurol. (2006) 59:174-177.
169. RJNNE JO, MYLLYKULA T, LONNBERG P et al.: A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res. (1991) 547:167-170.
170. QUIK M, BORDIA T, FORNO L et al.: Loss of α-conotoxinMII- and A85380-sensitivc nicotinic receptors in Parkinson's disease striatum. J. Neurochem. (2004) 88:668-679.
171. RUETER LE, DONELLY-ROBERTS DL, CURZON P et al.: A-85380: A pharmacological probe for the predinical and clinical investigation of the α4β2 neuronal nicotinic acetylcholine receptor. CNS Drug Rev. (2006) 12:100-112.
172. 123I]-A-85380. J. Label. Compd. Radiopharm. (2003) 46:S379.
173. KASSIOU M, EBERL S, MEIKLE SR et al.: In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT, Nucl. Med. Biol. (2001) 28:165-175.
174. NAVARRO HA, XU H, ZHONG D et al.: In vitro and in vivo characterization of [I-125]-iodomethyllycaconitine in the rat. Synapse (2002) 44:117-123.
175. DOLLE F, VALETTE H, HINNEN F et al.: Synthesis and preliminary evaluation of a carbon-11-labelled agonist of the α7 nicotinic acetylcholine receptor. J. Label. Compd. Radiopharm. (2001) 44:785-795.
176. POMPER MG, PHILLIPS E, FAN H et al.: Synthesis and biodistribution of ractiolabeled α7 nicotinic acetylcholine receptor figands. J. Nucl. Med. (2005) 46:326-334.
177. KHAN I, OSAKA H, STANISLAUS S et al.: Nicotinic acetylcholine receptor distribution in relation to spinal neurotransmission pathways. J. Comp. Neurol. (2003) 467:44-59.
178. KHAN I, WENNERHOLM M, SINGLETARY E et al.: Ablation of primary afferent terminals reduces nicotinic receptor expression and the nociceptive responses to nicotinic agonists in the spinal cord. J. Neurol. (2004) 33:543-556.
179. RASHID H, UEDA H: Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism. Brain Res. (2002) 953:53-62.
180. RASHID H, FURUE H, YOSHIMURA M, UEDA H: Tonic inhibitory role of α4β2 subtype of nicotinic acetylcholine receptors on nociceptive transmission in the spinal cord in mice. Pain (2006) 125:125-135.
181. HABERBERGER RV, BERNARDINI N, KRESS M, HARTMANN P, LIPS KS, KUMMER W: Nicotinic acetylcholine receptor subtypes in nociceptive dorsal root ganglion neurons of the adult rat. Autonomic Neurosci.: Basic and Chnical (2004) 113:32-42.
182. CORDERO-ERAUSQUIN M, PONS S, FAURE P, CHANGEUX JP: Nicotine differentially activates inhibitory and excitatory neurons in the dorsal spinal cord. Pain (2004) 109:308-318.
183. CUCCHIAR0 G, CHAIJALE N, COMMONS KG: The dorsal raphe nucleus as a site of action of the antinociceptive and behavioral effects of the α4 nicotinic receptor agonist epibatidine. J. Pharmacol. Exp. Ther. (2005) 313:389-394.
184. CUCCHIAR0 G, CHAIJALE N, COMMONS KG: The locus coeruleus as a site of action of the antinociceptive and behavioral effects of the nicotinic receptor agonist, epibaridine. Neuropharmacol. (2006) 50:769-776.
185. FREEDMAN R. Schizophrenia. N. Eng. J. Med. (2003) 349:1738-1749.
186. QUIK M, KULAK JM. Nicotine and nicotinic receptors: relevance to Parkinson's disease. Neurotoxicology (2002) 23:581-594.
187. SHAW S, BENCHERIF M, MARRERO MB: Janus Kinase 2, an early target of α7 nicotinic acetylcholine receptor-mediated nearoprotection against Aβ-(1-42) amyloid. J. Biol. Chem. (2002) 277:44920-44924.
188. SHAW S, BENCHERIF M, MARRERO MB: Angiotensin II blocks nicotine-mediated neuroprotection against β-Amyloid (1-42) via activation of the tyrosine phosphatase SHP-1. J. Neurosci. (2003) 23:11224-11228.